+

WO2006031312A3 - Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression - Google Patents

Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression Download PDF

Info

Publication number
WO2006031312A3
WO2006031312A3 PCT/US2005/027949 US2005027949W WO2006031312A3 WO 2006031312 A3 WO2006031312 A3 WO 2006031312A3 US 2005027949 W US2005027949 W US 2005027949W WO 2006031312 A3 WO2006031312 A3 WO 2006031312A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatments
compositions
activated cells
patients
myelosuppressed patients
Prior art date
Application number
PCT/US2005/027949
Other languages
English (en)
Other versions
WO2006031312A2 (fr
Inventor
Demao Yang
Original Assignee
Demao Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/939,168 external-priority patent/US7332158B2/en
Priority claimed from US10/939,302 external-priority patent/US20060057121A1/en
Application filed by Demao Yang filed Critical Demao Yang
Priority to EP05802443A priority Critical patent/EP1789089A4/fr
Priority to JP2007531171A priority patent/JP2008512454A/ja
Publication of WO2006031312A2 publication Critical patent/WO2006031312A2/fr
Publication of WO2006031312A3 publication Critical patent/WO2006031312A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des protocoles permettant d'activer des cellules sanguines humaines et de les administrer à des patients cancéreux, à des patients présentant une myélosuppression sévère, y compris à des patients présentant une myélosuppression sévère traités pour un cancer, par exemple par chimiothérapie ou radiothérapie. Le protocole peut comprendre la mise en culture de cellules sanguines en présence d'agents activants, tels qu'une cytokine ou et ionophore.
PCT/US2005/027949 2004-09-10 2005-08-05 Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression WO2006031312A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05802443A EP1789089A4 (fr) 2004-09-10 2005-08-05 Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression
JP2007531171A JP2008512454A (ja) 2004-09-10 2005-08-05 骨髄抑制患者に対する体外活性化細胞療法の構成と応用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/939,302 2004-09-10
US10/939,168 2004-09-10
US10/939,168 US7332158B2 (en) 2002-05-29 2004-09-10 Compositions and treatments for myelosuppression by ex vivo activated immune cells
US10/939,302 US20060057121A1 (en) 2004-09-10 2004-09-10 Compositions and treatments using ex vivo activated cells for myelosuppressed patients

Publications (2)

Publication Number Publication Date
WO2006031312A2 WO2006031312A2 (fr) 2006-03-23
WO2006031312A3 true WO2006031312A3 (fr) 2007-05-10

Family

ID=36060473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027949 WO2006031312A2 (fr) 2004-09-10 2005-08-05 Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression

Country Status (3)

Country Link
EP (1) EP1789089A4 (fr)
JP (1) JP2008512454A (fr)
WO (1) WO2006031312A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190298766A1 (en) * 2018-03-29 2019-10-03 Demao Yang Cell therapy for patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023060A1 (fr) * 1995-01-27 1996-08-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede pour isoler des cellules dendritiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023060A1 (fr) * 1995-01-27 1996-08-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede pour isoler des cellules dendritiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Ex Vivo Immunotherapy for Patients with Benzene-Induced Aplastic Anemia", J. HEMOTHERAPY, vol. 12, 2003, pages 505 - 514, XP008076645 *
LI ET AL.: "Ex Vivo Activated Immune Cells Promote Survival and Stimulate Multilineage Hematopoietic Recovery in Myelosuppressed Mice", J. IMMUNOTHER., vol. 28, no. 4, July 2005 (2005-07-01) - August 2005 (2005-08-01), pages 420 - 425, XP008076650 *
SHAH ET AL.: "Why do we Still Use Serum in the Production of Biopharmaceuticals", DEV. BIOL. STAND., vol. 99, 1999, pages 17 - 22, XP008076648 *

Also Published As

Publication number Publication date
EP1789089A2 (fr) 2007-05-30
EP1789089A4 (fr) 2009-08-26
WO2006031312A2 (fr) 2006-03-23
JP2008512454A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
MX2010005642A (es) Preparados, metodos y estuches para el tratamiento de la tos.
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
TW200606162A (en) Pyrazolopyridine derivatives
EP3248600B8 (fr) Combinaisons et modes d'administration d'agents thérapeutiques et thérapie combinée
TW200716646A (en) (S)-N-methylnaltrexone
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
WO2007128817A3 (fr) Dérivé insulinique
UA88647C2 (ru) C-арилгликозидные ингибиторы sglt2 и процесс лечения с их использованием
WO2008052770A3 (fr) Arn à base modifiée utilisé pour accroître l'expression d'une protéine
AU2003295644A1 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
TW200740451A (en) An agent for rising concentration of Adiponectin
IL173369A (en) Combined pharmaceutical preparation containing g - csf and p1gf effective in stimulating mobilization of peripheral blood progenitor cells
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
SE0300098D0 (sv) Use of cyclin D1 inhibitors
PT3295954T (pt) Agente para utilização no caso de intolerância intestinal à frutos
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques
WO2007048097A3 (fr) Derives de l'androsterone et leur procede d'utilisation
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
PL1869185T3 (pl) Koniugat zawierający białko P21 do leczenia raka
WO2006022612A3 (fr) Methodes d'utilisation de cellules regeneratrices dans le traitement d'accident vasculaire cerebral et de maladies et de troubles lies
WO2005123908A3 (fr) Nouvelles lignees cellulaires cancereuses et leurs utilisations
WO2005042699A3 (fr) Polypeptides modifies presentant une activite therapeutique et leurs methodes d'utilisation
WO2006031312A3 (fr) Compositions et traitements utilisant des cellules activees ex vivo pour patients presentant une myelosuppression
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007531171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005802443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580038456.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005802443

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载